ClinicalTrials.gg

Program

vonafexor

Also written as “EYP001a”, “Vonafexor” and “Vonafexor low dose”.

Its studies are mostly in Hepatitis B, Chronic · Non-alcoholic Fatty Liver Disease · Renal Insufficiency, Chronic · Nephritis, Hereditary, led by Enyo Pharma.

Furthest: phase 2, since Jan 17, 201911 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Enyo Pharma110 open or runningphase 2since Jan 17, 2019Mar 31, 2017none ahead

Also a collaborator on its studies: novotech-australia-pty-limited, synteract-inc, eurofins, parexel, cpr-pharma-services-pty-ltd-australia and pra-health-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 31, 2017First study: phase 1 study in HealthyFirst studyNCT03110276 · 80 enrolled
  2. Aug 31, 2017Phase 1 study in Hepatitis B, ChronicNCT03272009 · 73 enrolled · Australia, Netherlands, Poland and more
  3. Oct 20, 2017Phase 1 study in Hepatitis B, ChronicNCT03320616 · 11 enrolled · Netherlands
  4. Jan 29, 2018Phase 1 study in Hepatitis B, ChronicNCT03469583 · 16 enrolled · Australia
  5. Jan 17, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03812029 · 120 enrolled · United States, Belgium, France and more
  6. Jun 4, 2019Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT03976687 · 16 enrolled · Australia
  7. Jul 26, 2019Phase 1 study in HealthyNCT04037618 · 6 enrolled · Netherlands
  8. Apr 23, 2020Phase 2 study in Hepatitis B, ChronicNCT04365933 · 20 enrolled · Hong Kong, Korea, Republic of, Taiwan
  9. Jul 6, 2020Phase 2 study in Hepatitis B, ChronicNCT04465916 · 26 enrolled · Australia, Hong Kong, Korea, Republic of and more
  10. May 14, 2024Phase 2 study in Nephritis, HereditaryNCT06425055 · 26 enrolled · United States, France, Spain
  11. Apr 7, 2025Phase 2 study in Renal Insufficiency, ChronicNCT06939816 · 10 enrolled · Germany

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06939816Renal Insufficiency, Chronic · Germany2TerminatedDec 22, 202510
NCT06425055Nephritis, Hereditary · United States, France, Spain2CompletedSep 4, 202526
NCT04465916Hepatitis B, Chronic · Australia, Hong Kong, Korea, Republic of and more2TerminatedJun 17, 202126
NCT04365933Hepatitis B, Chronic · Hong Kong, Korea, Republic of, Taiwan2CompletedJun 16, 202120
NCT04037618Healthy · Netherlands1CompletedJul 27, 20196
NCT03976687Non-alcoholic Fatty Liver Disease · Australia1CompletedMay 25, 202016
NCT03812029Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more2CompletedJun 16, 2021120
NCT03469583Hepatitis B, Chronic · Australia1CompletedJun 20, 201816
NCT03320616Hepatitis B, Chronic · Netherlands1CompletedOct 12, 201711
NCT03272009Hepatitis B, Chronic · Australia, Netherlands, Poland and more1CompletedJul 30, 201873
NCT03110276Healthy1CompletedMar 201780

How it is read

Names in the registry

  • “EYP001a”, 6 entries
  • “Vonafexor”, 2 entries
  • “Vonafexor low dose”, 1 entry
  • “Vonafexor high dose”, 1 entry
  • “[14C]-EYP001a”, 1 entry

Codes read as this program: EYP001A, EYP001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.